Open-Label Treatment Extension Study

An Open-Label, Depot Buprenorphine (RBP-6000) Treatment Extension Study in Subjects With Opioid Use Disorder

Study is to provide ongoing treatment with RBP-6000 and safety monitoring for subjects who complete the RB-US-13-0003 study (NCT02510014) and for whom a new treatment venue has not been identified or arranged.

Study Overview

• Status: Completed
• Conditions: Opioid Use Disorder; Opioid-related Disorders
• Intervention / Treatment: Drug: RBP-6000

Detailed Description

This is a multi-center, open-label, RBP-6000 treatment extension study in which subjects who have completed the End of Study (EOS) procedures for study RB-US-13-0003 are eligible. EOS assessments completed at the RB-US-13-0003 EOS visit serve as part of the screening visit for this study. In addition, subjects were requested to complete a Columbia Suicide Severity Rating Scale (C-SSRS) baseline/screening survey and a medical history and height was obtained.

The informed consent may be shared with subjects up to 2 months prior to the RB-US-13-0003 EOS visit, however should not be signed until all assessments for the EOS visit have been completed.

On Day 1, eligible subjects receive a subcutaneous (SC) injection of RBP-6000 at a low or high dose based on the medical judgment of the investigator. After the injection, vital signs and the injection site were assessed. Prior to departing the site, subjects were also assessed for adverse events (AEs) and use of concomitant medications (ConMeds).

Subjects return to the site for monthly injection visits every 28 days (-2 / +7 days) for a total of up to 6 injections (participants were not required to complete all 6 injections). At each subsequent visit (Injections 2 through 6) the following procedures / assessments were performed : urine pregnancy test performed for all female subjects who are of childbearing potential before each injection; previous injection site assessed for potential reaction and evidence of attempts to remove the depot; vital signs collected pre and post each injection; RBP-6000 injection, urine drug screen (UDS); C-SSRS since last visit assessment, counseling (manual-guided behavioral therapy); use of ConMeds; local injection site grading, subject self-assessment of injection site pain (Injection Site Pain Visual Analog Scale [VAS]), assessment for adverse events (AEs).

Laboratory tests (hematology, chemistry and urinalysis) may be requested by the Investigator on an ad-hoc basis in order to assess for AEs.

A subject's alternative treatment options were assessed at least two months before EOS at each visit.

At EOS or early termination (ET), the following assessments were performed: urine pregnancy test performed for all female subjects who are of childbearing potential; vital signs; previous injection site assessed for potential reaction and evidence of attempts to remove the depot; UDS; C-SSRS since last visit assessment, counseling (manual-guided behavioral therapy); use of ConMeds; assessment for AEs; a brief physical exam; height and body weight were measured and a subject's body mass index (BMI) and waist-to-hip ratio calculated; laboratory tests (hematology, chemistry, urinalysis).

Subjects were to be contacted by telephone approximately 4 weeks after EOS/ET for a safety follow-up assessment of AEs and use of ConMeds.

• Study Type: Interventional
• Enrollment (Actual): 208
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Hamilton, Alabama, United States, 35570
      • Boyett Health Services
  • Arkansas
    • Little Rock, Arkansas, United States, 72211
      • Woodland International Research Group
  • California
    • Long Beach, California, United States, 90806
      • Collaborative Neuroscience Network
    • Oakland, California, United States, 94612
      • Pacific Research Partners
  • Florida
    • Gainesville, Florida, United States, 32607
      • Sarkis Clinical Trials
    • Jacksonville, Florida, United States, 32256
      • Amit Vijapura
    • Lakeland, Florida, United States, 33805
      • Meridien Research
    • Lauderhill, Florida, United States, 33319
      • Innovative Clinical Research
    • North Miami, Florida, United States, 33161
      • Scientific Clinical Research
  • Kansas
    • Prairie Village, Kansas, United States, 66206
      • Phoenix Medical Research
  • Louisiana
    • New Orleans, Louisiana, United States, 70114
      • Louisiana Research Associates
    • Shreveport, Louisiana, United States, 71101
      • Louisiana Clinical Research
  • Massachusetts
    • Fall River, Massachusetts, United States, 02720
      • Stanley Street Treatment and Resources
    • Watertown, Massachusetts, United States, 02472
      • Adams Clinical Trials
  • Mississippi
    • Flowood, Mississippi, United States, 39232
      • Precise Research Centers, Inc.
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • St Louis Clinical Trials
  • Nevada
    • Las Vegas, Nevada, United States, 89102
      • Altea Research
  • New Jersey
    • Berlin, New Jersey, United States, 08009
      • Hassman Research Institute
    • Cherry Hill, New Jersey, United States, 08002
      • Center For Emotional Fitness
  • Ohio
    • Canton, Ohio, United States, 44708
      • Neuro-Behavioral Clinical Research
    • Dayton, Ohio, United States, 45417
      • Midwest Clinical Research Center
    • Garfield Heights, Ohio, United States, 44125
      • Rakesh Ranjan MD & Associates, Inc.
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73112
      • SP Research, PLLC
    • Oklahoma City, Oklahoma, United States, 73112
      • Pahl Pharmaceutical Professionals
  • Oregon
    • Portland, Oregon, United States, 97232
      • CODA
  • Pennsylvania
    • Altoona, Pennsylvania, United States, 16601
      • Keystone Clinical Solutions
  • South Carolina
    • Charleston, South Carolina, United States, 29407
      • Carolina Clinical Trials
  • Texas
    • Dallas, Texas, United States, 75243
      • Pillar Clinical Research
    • DeSoto, Texas, United States, 75115
      • Insite Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Provide written consent to participate in this study.
2. Completed the End of Study Visit for the RB-US-13-0003 study (NCT02510014).
3. Be considered eligible in the medical judgment of the Investigator.

4. Females: Women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to informed consent form (ICF)) must have a negative pregnancy test prior to enrollment and must agree to use a medically acceptable means of contraception from screening through at least 6 months after the last dose of investigational medicinal product (IMP).

   Males: Subjects with female partners of child-bearing potential must agree to use medically acceptable contraception after signing the ICF through at least 6 months after the last dose of IMP. Male subjects must also agree not to donate sperm during the study and for 6 months after receiving the last dose of IMP.

5. Subjects must agree not to take any buprenorphine products other than those administered during the current study throughout participation in the study.
6. Subjects must be willing to adhere to study procedures.

Exclusion Criteria:

1. Subject compliance issues during participation in the RB-US-13-0003 study which, in the opinion of the Investigator, could potentially compromise subject safety.
2. Women of childbearing potential who have a positive pregnancy test at RB-US-13-0003 at the end-of-study (EOS) visit, who are pregnant or breastfeeding, seeking pregnancy, or failing to use adequate contraceptive methods during the study.
3. History of suicidal ideation within 28 days prior to signing the ICF as evidenced by answering "yes' to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) "since last visit" assessment (completed in the EOS Visit for Study RB-US-13-0003), screening/baseline" assessment for the current study), or history of a suicide attempt (per the C-SSRS) in the 6 months prior to signing the ICF.
4. Taking any cytochrome P450 3A4 and 2C8 inducers and inhibitors, self-reported additional buprenorphine, or over the counter (OTC) and/or herbal supplements with the potential to prolong QTc within 28 days of Day 1 unless prior written approval was obtained from the Medical Monitor.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: RBP-6000 (100/300 mg Flex); On Day 1 of the study all eligible subjects received a single subcutaneous (SC) injection of RBP-6000. Participants returned to the site for monthly injection visits every 28 days (-2/+7 days) for a total of up to 6 injections. Participants were not required to complete all 6 injections and could choose to terminate from the study at any time. For each injection, participants could receive either a dose of 100 mg RBP-6000 or 300 mg RBP-6000, based on the medical judgement of the investigator.

Drug: RBP-6000; Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.; Other Names: extended-release buprenorphine; atrigel buprenorphine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period	TEAE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= a marked limitation in activity. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical or surgical intervention to prevent one of the outcomes listed in this definition.	Day 1 up to Week 29
Percentage Change From Baseline to Week 25 in Vital Signs	Vital signs include: systolic blood pressure (mmHg); diastolic blood pressure (mmHg); respiratory rate (breaths/minute); pulse oximetry (%); pulse rate (beats/min); temperature (C)	Day 1, Week 25
Participants With Treatment-emergent Adverse Events (TEAEs) Pertaining to Laboratory Test Values	TEAE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. The number of participants with TEAEs specific to laboratory tests are summarized.	Day 1 up to Week 25

Collaborators and Investigators

• Sponsor: Indivior Inc.

Publications and helpful links

General Publications

• Craft WH, Tegge AN, Keith DR, Shin H, Williams J, Athamneh LN, Stein JS, Chilcoat HD, Le Moigne A, DeVeaugh-Geiss A, Bickel WK. Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study. Drug Alcohol Depend. 2022 May 1;234:109389. doi: 10.1016/j.drugalcdep.2022.109389. Epub 2022 Mar 9. Erratum In: Drug Alcohol Depend. 2022 Dec 1;241:109687.

Study record dates

Study Major Dates

• Study Start (Actual): August 17, 2016
• Primary Completion (Actual): August 23, 2017
• Study Completion (Actual): August 23, 2017

Study Registration Dates

• First Submitted: September 6, 2016
• First Submitted That Met QC Criteria: September 6, 2016
• First Posted (Estimate): September 12, 2016

Study Record Updates

• Last Update Posted (Actual): November 29, 2018
• Last Update Submitted That Met QC Criteria: November 2, 2018
• Last Verified: November 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Pathologic Processes; Substance-Related Disorders; Narcotic-Related Disorders; Disease; Opioid-Related Disorders; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Narcotic Antagonists; Buprenorphine
• Other Study ID Numbers: INDV-6000-301

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes